SGO 2023 Conference Coverage on VuMedi
SGO 2023 Phase 3 UP-NEXT Trial: Upifitamab Rilsodotin, a NaPi2b-Directed ADC, in Platinum-Sensitive Recurrent Ovarian Cancer
By
SGO 2023 Conference Coverage on VuMedi
FEATURING
Debra Richardson
By
SGO 2023 Conference Coverage on VuMedi
FEATURING
Debra Richardson
Comments 0
Login to view comments.
Click here to Login
